Navigation Links
US Senate Votes against Testing of Pesticide on Humans

The US congress is considering whether to temporarily ban the Environmental Protection Agency (EPA) from using human tests to determine whether a pesticide should be marketed//. Lawmakers on Capitol Hill will soon decide whether to place a one year moratorium on the conduct and use of studies that expose participants to pesticides. In most cases, trials are conducted by companies seeking to have their pesticides approved by the agency for marketing.

The Republican controlled US senate voted 60 to 37 to enact, such a moratorium, in an amendment to the spending bill that funds the EPA. The amendment would prohibit the agency, beginning on 1 October, from conducting human exposure tests or using data from tests conducted by third parties in its pesticide risk assessments. An identical amendment was passed by the House in May.

The Pesticide companies became interested in human testing seemingly in a bid to circumvent a 1996 law that made it more difficult to use animal tests to meet agency standards for protecting vulnerable populations such as children from pesticide residues. The EPA now considers human testing data on a case by case basis, rejecting only experiments deemed scientifically unsound or ‘fundamentally unethical’ by EPA staff.

“The moral and ethical issues surrounding these pesticide experiments are overwhelming,” California Democratic Senator Barbara Boxer, who introduced the amendment, said after the vote. The Pesticide industry, represented by the Washington lobbying group CropLife America, adds that it is ‘troubled by the blatant manipulation of the facts’ by Democratic senators. “Sound science and public health protections have affirmed the safety and ethics of human data studies,’ the group said in its statement.

An alternative amendment, sponsored by Republican Senator Conrad Burns, also passed the senate by a vote of 57 to 40. That version would allow the EPA to use third party human tests in licensin
'"/>




Page: 1 2

Related medicine news :

1. Senate assures ban on smoking
2. US Senate Approves Embryo-research Plan Despite Presidents Refusal
3. Senate Committee Approves Telemedicine Mental Health Bill
4. US Senate Passes Stem Cell Research Bill
5. Multi billion-dollar suit filed against cell phone firm for causing brain tumours
6. Man against HIV – new vaccine ready for human trials
7. Antibiotics losing their power against acne
8. South Africa Wins landmark case against pharmaceutical giants
9. Vitamin E, the latest warrior against diabetes
10. Acne may protect against infections
11. Fight against E.coli
Post Your Comments:
(Date:5/16/2008)...e/ -- ExamForce announced today the,hiring of John...es Manager.,Mongeon formerly headed up the Governm... oversaw government sales and marketing initiative...y certifications in the IT,industry., Mongeon, a ...C)2,Americas to spend more time with his two-year ...
(Date:5/16/2008)...7 Comprehensive Income increased 42% to $9.7 milli..., - 2007 Gross Margin of 76%, - Product Sales Ba... million from $2.4 million as of December 31, 2...irstCall/ -- Huiheng,Medical, Inc. ("Huiheng" or t...based leader in the development, sales and support...
(Date:5/16/2008)...ree for at least a year or two, , , F...et cells help people with type 1 diabetes live ins...o provide longer-term improved metabolic control e..., researchers report. , Using continuous glucos...ity of Miami Miller School of Medicine found that ...
(Date:5/16/2008)...ire-USNewswire/ -- Karin Weisburgh,senior researc...her of,Consumer Reports magazine, was named Westch... Yonkers headquarters today., Ms. Weisburgh commu...n,the winter and rides in shirt sleeves in the sum...er Ridge in New Rochelle, down Mill Road in,Eastch...
Breaking Medicine News(10 mins):Health News:Huiheng Medical, Inc. Reports Record Financial Results for Fiscal Year 2007 and Financial Results for Q1 2008 2Health News:Huiheng Medical, Inc. Reports Record Financial Results for Fiscal Year 2007 and Financial Results for Q1 2008 3Health News:Huiheng Medical, Inc. Reports Record Financial Results for Fiscal Year 2007 and Financial Results for Q1 2008 4Health News:Huiheng Medical, Inc. Reports Record Financial Results for Fiscal Year 2007 and Financial Results for Q1 2008 5Health News:Huiheng Medical, Inc. Reports Record Financial Results for Fiscal Year 2007 and Financial Results for Q1 2008 6Health News:Islet Cell Transplants Aid Type 1 Diabetics 2Health News:Islet Cell Transplants Aid Type 1 Diabetics 3Health News:Westchester Cycle Club Awards Consumers Union Staffer Karin Weisburgh Commuter of the Year 2Health News:Westchester Cycle Club Awards Consumers Union Staffer Karin Weisburgh Commuter of the Year 3
...therhead P.E.T. Center for Preventing and Reversin..., have suggested in a new study that intense lifes...duces myocardial perfusion abnormalities and cardi...olesterol lowering drugs. They studied 409 patient...
...at the Johns Hopkins School of Public Health has c...tists have called for urgent research into the imp...rats which suggest a chemical in soya can damage t...evidence to suggest it has a similar effect on hum...
... damage to the DNA within our cells, which could l... a molecule that triggers a protective mechanism i...ces severely damaged cells to destroy themselves. ...otection mechanism, was discovered by researchers ...
...ith the Max Planck Institute, has succeeded in fin...ich researchers claim is a breakthrough technology... insights into the biologic function of neurons, n...'s Neuro-Chip is based on a standard complementary...
Other Medicine News:
(Date:5/16/2008)...ation of a Small Molecule with D...if., May 16 /- Nektar,Thera... today from a Phase 1,study of NKTR- 102, PEGylate...r activity in patients with refractory solid tumor... molecule PEGylation technology,produced an increa...
(Date:5/15/2008)...ion Most Affected by Disease -, WAYNE, N.J. and E...-,Bayer HealthCare Pharmaceuticals, Inc. and Onyx ...nced that Nexavar(R) (sorafenib) tablets,significa...=0.68;,p-value=0.014) in patients in the Asia-Paci...(HCC), or primary liver cancer versus those,receiv...
(Date:5/15/2008)...state, Colorectal and Ovarian ...vent on Sun., June 1 with Oncology Experts -, SOU...Call/ -- Poniard,Pharmaceuticals, Inc. (Nasdaq: P...logy, today announced that the Company will presen...n various tumor types and combinations, at,poster ...
(Date:5/15/2008)...cks, Hispanics/Latinos, People wi...J., May 15 /- Daiichi Sankyo, Inc.,a... Society of,Hypertension,s Twenty- Third Annual Sc...rated that the powerful combination drug AZOR(TM),...ffectively helped,patients across several major su...
Breaking Medicine Technology:Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings 2Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings 3Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings 4Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings 5Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study 2Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study 3Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study 4Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study 5Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study 6Poniard to Present Clinical Data From Picoplatin Trials in Multiple Tumor Types at American Society of Clinical Oncology 2008 Annual Meeting 2Poniard to Present Clinical Data From Picoplatin Trials in Multiple Tumor Types at American Society of Clinical Oncology 2008 Annual Meeting 3Poniard to Present Clinical Data From Picoplatin Trials in Multiple Tumor Types at American Society of Clinical Oncology 2008 Annual Meeting 4Poniard to Present Clinical Data From Picoplatin Trials in Multiple Tumor Types at American Society of Clinical Oncology 2008 Annual Meeting 5Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 2Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 3Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 4Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 5Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 6Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 7Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008 2329 1Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008 2329 2Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008 2329 3Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008 2329 4Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008 2329 5CTDC Announces the Disposal of Non core Business 2326 1CTDC Announces the Disposal of Non core Business 2326 2Global warming and other research from UCLA summit featured in journal 1684 1Global warming and other research from UCLA summit featured in journal 1684 2The Long Term Care Insurance Explosion 3B January Conference to Celebrate Rapid Growth of LTC Protection and Light Fuse of Further Expansion 8598 1The Long Term Care Insurance Explosion 3B January Conference to Celebrate Rapid Growth of LTC Protection and Light Fuse of Further Expansion 8598 2
...nix, Inc. (CYGX.OB),announced today that it has su... a novel synDNA(TM) vaccine designed for humans,(t...ian (H5N1),influenza virus. The study clearly demo...d with the Company,s synDNA(TM) vaccine,whereas al...oups,were challenged with a highly virulent strain...
...ERBITUX with,chemotherapy in recurrent and/or meta... of improving overall survival --, NEW YORK, April...s Incorporated and Bristol-Myers Squibb Company an... ERBITUX(R) (Cetuximab),combined with platinum-bas...sing overall survival in patients with recurrent a...
Other Medicine Technology:CytoGenix Announces Successful Testing of synDNA Vaccine for Avian,Influenza Virus 2Survival Data Available From Erbitux Study in First-Line Treatment,of Advanced Head and Neck Cancer 2Survival Data Available From Erbitux Study in First-Line Treatment,of Advanced Head and Neck Cancer 3Survival Data Available From Erbitux Study in First-Line Treatment,of Advanced Head and Neck Cancer 4Survival Data Available From Erbitux Study in First-Line Treatment,of Advanced Head and Neck Cancer 5Survival Data Available From Erbitux Study in First-Line Treatment,of Advanced Head and Neck Cancer 6Survival Data Available From Erbitux Study in First-Line Treatment,of Advanced Head and Neck Cancer 7Survival Data Available From Erbitux Study in First-Line Treatment,of Advanced Head and Neck Cancer 8Survival Data Available From Erbitux Study in First-Line Treatment,of Advanced Head and Neck Cancer 9
The Reusable Purse String Clamp is intended for use in the mechanical construction of a purse string suture. The clamp can be used on any part of the gastrointestinal tract except the esophagus.
VALTRAC™ Sizer Device for use with VALTRAC™ Devices (Single Use Biofragmentable Anastomosis Ring)., ,The Purstring™ Device is indicated in intestinal, colorectal and esophageal sur
...gle use instrument to create an automatic purse-st...G™ 45 disposable instrument has application ... cardiac surgery for temporary and permanent purse...posable instrument has application in intestinal, ...
...lizing a single use loading unit (SULU), the EEA&t...titanium staples., ,Immediately after staple form... excess tissue, thus creating a circular anastomos...andles firmly as far as they will go. The diameter...
Medicine Products: